Inactive Instrument

Endocyte, Inc. Stock

US29269A1025

Biotechnology & Medical Research

News in other languages: Endocyte, Inc.

14/11/18	PHARMA-L'allemand Merck abaisse sa prévision de bénéfice annuel
13/11/18	PHARMA-Bayer résiste au T3, malgré l'euro fort et la santé animale
08/11/18	PHARMA-AstraZeneca prévoit des années de croissance
06/11/18	PHARMA-Eli Lilly relève sa prévision annuelle de bénéfice
02/11/18	PHARMA-AbbVie dépasse les attentes et relève sa prévision de bénéfice

More news

Managers and Directors: Endocyte, Inc.

Manager	Title	Age	Since
John McKenna PSD	President	-	-
Iontcho Vlahov PRN	Corporate Officer/Principal	-	19/07/2011

Director	Title	Age	Since
John McKenna CHM	Chairman	-	-

More insiders

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Employees

Sector

Biotechnology & Medical Research

More about the company

-40%: Exceptional extension

SEIZE THE OFFER!

02/11/18	Bayer : CEO backs group's diversified structure	RE
23/10/18	AstraZeneca : digs deeper into cancer with Innate stake	RE
18/10/18	European shares edge up as earnings flurry quells Fed angst	RE
18/10/18	Endocyte : Novartis pushes deeper into nuclear medicine with $2.1 billion deal	RE
18/10/18	Endocyte : Novartis raises 2018 sales outlook as Entresto, Cosentyx accelerate	RE

20/12/18	Endocyte Stockholders Approve Merger Agreement with Novartis AG	GL
08/11/18	Endocyte Provides Third Quarter 2018 Financial Results and Operational Update	GL
18/10/18	Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion	GL
03/10/18	Endocyte becomes first Purdue startup to reach $1.5B in value	GL
27/09/18	Endocyte to Present at Two Investor Conferences on October 2nd	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENDOCYTE, INC.	-.--%	+0.54%	-	-	0
WUXI APPTEC CO., LTD.	+4.98%	+11.06%	+54.45%	+109.45%	70.88B
ARGENX SE	-0.39%	+1.66%	+38.84%	+78.01%	62.49B
WUXI BIOLOGICS (CAYMAN) INC.	+5.26%	+12.77%	+40.29%	+26.34%	26.34B
INSMED INCORPORATED	+2.49%	-3.12%	-16.30%	+360.84%	26.21B
BIONTECH SE	+2.08%	-0.85%	-0.71%	-7.90%	24.13B
GENMAB A/S	0.00%	+6.81%	+24.48%	-11.44%	20.72B
PHARMAESSENTIA CORPORATION	-2.54%	-10.16%	+149.64%	+313.93%	15.69B
EXELIXIS, INC.	-1.11%	+1.64%	+44.34%	+164.74%	14.46B
SUMMIT THERAPEUTICS INC.	-5.27%	-8.09%	-11.36%	+825.14%	14.24B
Average	+0.56%	+1.96%	+35.96%	+206.57%	30.57B
Weighted average by Cap.	+1.64%	+2.90%	+37.21%	+150.51%

Endocyte, Inc. Stock

Stocks

US29269A1025

Biotechnology & Medical Research

Latest news: Endocyte, Inc.

Press Releases: Endocyte, Inc.

News in other languages: Endocyte, Inc.

Managers and Directors: Endocyte, Inc.

Bio Therapeutic Drugs

Company Profile